IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer

NCT07674615 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

19

Enrollment

OTHER_GOV

Sponsor class

Conditions

Epithelial Ovarian Cancer
Fallopian Tube Cancers
Primary
Primary Peritoneal Carcinoma

Interventions

DRUG: Sacituzumab govitecan monotherapy

Sponsor

Shanghai Gynecologic Oncology Group